| 研究実績の概要 |
Controlling hematogenous metastases is an effective treatment strategy for colorectal cancer. The prokineticin family of angiogenic factors has the potential of becoming target molecules. Among them, prokineticin1 (PROK1) is involved in the promotion of angiogenesis, tumor growth, and liver metastases in colorectal cancer. We found that anti-PROK1 antibody and verified its effect in inhibiting liver metastases and prolonging survival.
The method involved creating liver metastasis model mice using human colorectal cancer cell lines. Mice were treated intraperitoneally with antibodies every 3 days. The number of metastatic lesions decreased and survival time was significantly prolonged in the antibody-treated group. Furthermore, using microarray, we confirmed the effect of administering the anti-PROK1 monoclonal antibody on the oxidation, reduction, and apoptotic processes, and cell division of tumors, and that alterations were suppressed in 72.1% of the genes examined.
We found a new mechanism of anti-PROK1 antibody, and might be the first step toward a new therapy.
|
